Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
about
ZAP-70 in B cell malignanciesFunctional and prognostic role of ZAP-70 in chronic lymphocytic leukaemiaEvolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathologyCXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia.Predicting survival in chronic lymphocytic leukemia.Progranulin is a novel independent predictor of disease progression and overall survival in chronic lymphocytic leukemia.B-1 cell lymphoma in mice lacking the steroid and xenobiotic receptor, SXR.ZAP70 Expression Within del6q21, del11q13 and del17p13 Cytogenetic Subgroups of Iranian Patients with Chronic Lymphocytic LeukemiaState-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.The steroid and xenobiotic receptor negatively regulates B-1 cell development in the fetal liver.Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation.CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia.A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLLCD38 and chronic lymphocytic leukemia: a decade later.Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaThe role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia.Prognostic factors in CLLGene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNADetection methods of ZAP-70 in chronic lymphocytic leukemia.Surface profiles for subclassification of chronic lymphocytic leukemia.Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia.RGS1 expression is associated with poor prognosis in multiple myeloma.State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia.Time-resolved Förster-resonance-energy-transfer DNA assay on an active CMOS microarray.Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients.CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism.Shorter telomeres correlate with an increase in the number of uniparental disomies in patients with chronic lymphocytic leukemia.Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas.Autoimmune haemolytic anaemia emerging during Campath treatment in a patient with CD5 negative chronic lymphocytic leukaemiaSignificance of t (8: 14) in CLL?Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance.
P2860
Q28279902-E9AD67F0-2D1B-4555-BCD6-5842931950B6Q28282822-2708EF79-D7B3-456B-BC6C-035EA3BD622BQ28287124-5F32975C-C65E-4E65-AA40-F1FD8D96A905Q33829089-CD105EFF-0390-4FD9-8EEA-25F1CDEFE36AQ33886052-130F178C-FAF7-4734-B58B-2D6AF50FCEDEQ34081881-14159E64-8AA9-4270-A507-A827075FC42FQ34095636-AD007F76-F3DB-4CBB-8300-1CD5F252737EQ34122737-C983E4D5-0F65-4494-8ADE-9E42A4376A6DQ34217900-87167877-0DE0-40A9-9D67-4C51EA12A765Q34257190-574B5EE4-EEB8-475F-AAE1-FF4EC0A3ABCDQ34979505-770CBCF7-AEAA-48CF-8B9A-843B001B2DBFQ35001297-40C17700-1A38-4CD4-89C5-A2BAC918D442Q35087595-20FBC1F0-FF34-40A0-BC1B-A143273EE281Q35860550-DE1434C9-7C97-4BF0-9C19-AF1B80940D5CQ35861964-68D409DE-A267-4270-A58C-235CA2066540Q35954301-EF1E4577-A483-4DFC-8650-E22761481066Q35970050-CBDFAB26-0626-42BF-B9DF-1CCEB03CA5C2Q36124370-AE766871-D9E6-4CDA-A0AB-95B93D947FBEQ36384860-9C78EF1D-064C-4E4F-A9E4-7F715D7AF582Q36439969-C34E6CBE-611A-4CE6-8C68-CA9BE5538F26Q36544938-519AC3EE-DE91-4139-9126-0FF07DB1C367Q36615126-1837BFC1-3D99-459E-B55B-CF1D4D0BC22BQ36843749-2B27ED60-53E9-41BC-A02B-7166A58F099EQ36849336-4B222B6E-C031-40D8-8D22-DBE9AB5C92FDQ36852233-B2C60776-9588-444E-9E58-3C8A97853C30Q37207766-45EB3D87-6705-4B26-BBF1-5D01C5FFB585Q37892409-CE56E4C8-9A32-4551-9F0D-9517C3269EF6Q37948956-E913B3FC-AD07-4FC7-86DB-5F9CC3FEB698Q38042778-6E247351-A31F-46F0-88AA-6DB196E1D4BCQ38756525-E2C3390C-1531-4790-B548-AC3954375A6EQ39085428-1707974B-0BAC-43C2-90D2-DC6F53C18B3CQ39848178-AFB81605-CED0-463E-862C-58D11A433E5FQ40138593-561B08F3-054E-4695-95C0-EF45DE9177D1Q40276341-C0389E8D-4A77-4DCB-B3C5-D120EC6E6793Q41233958-E0F8EDF2-186C-458A-BBE0-259BDE5BD4C4Q41495243-9B65FFBD-6A47-4243-A07B-0AFE34ADAEBBQ41693758-BCF3F650-CC86-4B7C-971E-34F6313A48BBQ42041997-9EB8FCC6-0DDF-49E8-991D-69F53649464AQ42134533-876DE4CC-802D-4C68-9BB1-C7CBF6917415Q42702972-B4C33FE6-6AB3-4C53-B94C-BDF1B618A047
P2860
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Combined analysis of ZAP-70 an ...... chronic lymphocytic leukemia.
@en
Combined analysis of ZAP-70 an ...... chronic lymphocytic leukemia.
@nl
type
label
Combined analysis of ZAP-70 an ...... chronic lymphocytic leukemia.
@en
Combined analysis of ZAP-70 an ...... chronic lymphocytic leukemia.
@nl
prefLabel
Combined analysis of ZAP-70 an ...... chronic lymphocytic leukemia.
@en
Combined analysis of ZAP-70 an ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Combined analysis of ZAP-70 an ...... chronic lymphocytic leukemia.
@en
P2093
Griesinger F
Klein-Hitpass L
Schroers R
Sellmann L
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403707
P577
2005-05-01T00:00:00Z